ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 98 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,256,230 | -36.1% | 4,220,048 | 0.0% | 2.22% | +1.4% |
| Q2 2023 | $31,692,560 | +66.2% | 4,220,048 | 0.0% | 2.19% | +65.3% |
| Q1 2023 | $19,074,617 | +40006.4% | 4,220,048 | 0.0% | 1.32% | -75.8% |
| Q4 2022 | $47,560 | -99.9% | 4,220,048 | 0.0% | 5.48% | +22.8% |
| Q3 2022 | $40,386,000 | +18.3% | 4,220,048 | 0.0% | 4.46% | +30.1% |
| Q2 2022 | $34,140,000 | -52.1% | 4,220,048 | 0.0% | 3.43% | -30.2% |
| Q1 2022 | $71,319,000 | -21.4% | 4,220,048 | 0.0% | 4.91% | -10.2% |
| Q4 2021 | $90,689,000 | -70.9% | 4,220,048 | 0.0% | 5.47% | -60.9% |
| Q3 2021 | $311,693,000 | +35.1% | 4,220,048 | 0.0% | 14.00% | +40.1% |
| Q2 2021 | $230,752,000 | -25.8% | 4,220,048 | 0.0% | 9.99% | -8.7% |
| Q1 2021 | $311,186,000 | -14.5% | 4,220,048 | 0.0% | 10.94% | -32.6% |
| Q4 2020 | $363,768,000 | +128.4% | 4,220,048 | 0.0% | 16.23% | +76.4% |
| Q3 2020 | $159,265,000 | – | 4,220,048 | – | 9.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $715,272,000 | 67.97% |
| Logos Global Management LP | 3,156,981 | $232,796,000 | 22.72% |
| Vivo Capital, LLC | 4,220,048 | $311,186,000 | 10.94% |
| Foresite Capital Management IV, LLC | 785,945 | $57,956,000 | 6.94% |
| Foresite Capital Management V, LLC | 320,000 | $23,597,000 | 6.94% |
| Board of Trustees of The Leland Stanford Junior University | 518,822 | $38,258,000 | 3.38% |
| Cormorant Asset Management, LP | 881,770 | $65,022,000 | 1.45% |
| Redmile Group, LLC | 978,600 | $72,162,000 | 1.02% |
| SPHERA FUNDS MANAGEMENT LTD. | 130,351 | $9,612,000 | 0.74% |
| Artal Group S.A. | 525,000 | $38,714,000 | 0.68% |